SANA today
$2.01-$0.28 (-12.23%)close Nov 12, 2026Trend
DailyDowntrend (starting)
4 hourLeaning Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $4.21
Key levels
Resistance$2.28
Resistance$2.04
Support$1.63
Support$1.32
Latest news & SEC filings
EarningsSana Biotechnology Posts Q3 2026 Results, Business Update
EarningsSana Biotechnology posts Q3 adjusted loss per share of $0.14, topping $0.15 consensus
EarningsSana Biotechnology to report Q3 2026 financial results
All SANA news →About Sana Biotechnology
Sana Biotechnology is a clinical-stage biopharmaceutical company developing engineered cell therapies. Its ex vivo hypoimmune platform aims to create allogeneic cells that evade immune rejection, with lead candidate SC451 for type 1 diabetes. Its in vivo fusogen platform delivers genetic payloads to specific cells, with lead candidate SG293 for B cell cancers and autoimmune diseases. The company operates in the United States.
Based on the company's 10-K filed Mar 3, 2026.
Nasdaq · Healthcare
Sana Biotechnology, Inc. (SANA)
What Is the Price Target for SANA?
SEPT Low Target
$6.00
SEPT Mid Target
$6.50
SEPT High Target
$7.00
Analyst Consensus
$6.50
Is SANA a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SANA.
Start Free Trial →Is SANA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$5.22
2
Moat Score
NONE
1/9
Piotroski Score
-6.5
Altman Z-Score
What Is Smart Money Doing with SANA?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Bishop Hans Edgar | director | Buy | 8,680 | - | Oct 5, 2026 |
| PATEL DHAVALKUMAR DHIRAJLAL | officer | Sale | 41,158 | $169K | Aug 27, 2026 |
| PATEL DHAVALKUMAR DHIRAJLAL | officer | Buy | 125,000 | - | Aug 26, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SANA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
17.24%
FCF Growth YoY
43.6%
Revenue Trend
UNKNOWN
Dark Pool Trades for SANA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SANA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:40:40 | $2.01 | 1,201 | $$2K | SELL |
| 21:28:56 | $2.05 | 1,280 | $$3K | BUY |
| 20:59:58 | $2.00 | 4,900 | $$10K | MIDPOINT |
| 20:59:58 | $2.00 | 2,438 | $$5K | MIDPOINT |
| 20:59:58 | $2.00 | 3,400 | $$7K | MIDPOINT |
5 dark pool trades shown · $$27K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for SANA
PREVIEWSEPT Investing provides real-time options flow tracking for SANA, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $2 | Jan 15 | 64 | $$40 | 1 | SWEEP |
| CALL | $5 | Jan 15 | 64 | $$35 | 7 | SWEEP |
| CALL | $7.5 | Jan 15 | 64 | $$635 | 127 | BLOCK |
| CALL | $2.5 | Jan 15 | 64 | $$2500 | 100 | BLOCK |
| CALL | $2 | Jan 21 | 435 | $$300 | 3 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Sana Biotechnology, Inc. (SANA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SANA — frequently asked questions
What is SANA stock price today?
Sana Biotechnology, Inc. (SANA) is at $2.01, down 12.23% (-$0.28) at the Nov 12, 2026 close.
Why is SANA stock moving today?
Latest SANA news — Nov 5, 2026: Sana Biotechnology Posts Q3 2026 Results, Business Update · Nov 5, 2026: Sana Biotechnology posts Q3 adjusted loss per share of $0.14, topping $0.15 consensus
What is the SANA price target?
The average analyst price target for SANA is $6.50, ranging from $6 to $7, based on 2 analysts. Latest: B of A Securities maintains on Aug 14, 2026.
What do analysts rate SANA?
Analyst ratings for SANA: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did SANA beat earnings?
SANA last reported on Aug 10, 2026: EPS -$0.22 vs -$0.15 expected — a miss of 49.8%.
Does SANA pay a dividend?
SANA does not currently pay a dividend.
What are SANA support and resistance levels?
Support: $1.63, $1.32. Resistance: $2.04, $2.28, $2.58.
What are insiders doing with SANA?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on SANA?
Nov 5, 2026: Sana Biotechnology Posts Q3 2026 Results, Business Update · Nov 5, 2026: Sana Biotechnology posts Q3 adjusted loss per share of $0.14, topping $0.15 consensus · Nov 5, 2026: Sana Biotechnology to report Q3 2026 financial results